Akeso.
Chinese Biopharmaceutical Company
- Reports this week
- 2
- Active events
- 1
- Connections
- 21
What's happening
Active this week
Earlier this month
One to three months ago
-
Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.Well supported6 reports
-
A collection of industry news reported on June 6th, including Akeso's success reported by China Daily, the general trend of Chinese companies outpacing Western counterparts, and the ASCO meeting held in Chicago.Well supported6 reports1 development inside
No events began in the chosen period. Widen it, or reset.
Around Akeso this week
News at the entities that move Akeso most-
MSD OperationalMSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Moves Akeso
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Akeso
-
Merck OperationalEli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Moves Akeso
-
AstraZeneca OperationalAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves Akeso
-
Guangdong Shared contextUnionPay reports on spending trends and plans marketing campaigns for Macau cardholders spending in Guangdong.Moves Akeso
-
China Daily StructuralZhu Min, a former deputy governor, spoke to China Daily about trade composition.Moves Akeso
Connections
The 19 strongest of 21, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Summit Therapeutics Structural
Summit Therapeutics relies on Akeso's core IP and engineering expertise for the co-development and commercialization of ivonescimab.
-
Xia Yu Structural
Xia Yu is the founder, chairwoman, and CEO of Akeso.
-
Yu Xia Structural
Yu Xia serves as the President and CEO of Akeso.
-
MSD Operational
Akeso and MSD are direct competitors whose drugs are being evaluated against each other in clinical trials.
-
FDA Structural
The FDA formally monitors and regulates Akeso's drug development process for U.S. market approval.
-
Merck Operational
The companies are actively competing in the market, evidenced by the emergence of conflicting clinical data regarding their respective drug pipelines.
-
Innovent Biologics Operational
Both companies are identified as key players and competitors within the Chinese biopharma sector.
-
Janus Henderson Transactional
Janus Henderson is backing biotech reverse mergers, indicating an investment relationship with Akeso.
Show all 19 connections
-
AstraZeneca Operational
Akeso's drug successfully outperformed AstraZeneca's Imfinzi in head-to-head clinical trials, indicating direct market competition.
-
Sanofi Mentioned together
The entities are mentioned within a broader context discussing the growth trends of Chinese versus Western companies.
-
China Daily Structural
Akeso utilizes China Daily as a platform to report and disseminate information regarding its successes and market presence.
-
Chicago Shared context
The company was relevant to the industry conference (ASCO) held in the city.
-
Summit Operational
Akeso and Summit are actively collaborating on the joint development of the drug ivonescimab.
-
Guangdong Shared context
Akeso is a company located in Guangdong Province, benefiting from its regional biopharma ecosystem.
-
Pfizer Shared context
The companies operate within a market context where Chinese companies are observed to be growing faster than Western counterparts.
-
Zhongshan Shared context
Akeso is a company headquartered in the city of Zhongshan.
-
DeepSeek Mentioned together
Akeso and DeepSeek are grouped together in the context of comparing their recent growth trajectories.
-
Eli Lilly and Company Mentioned together
Akeso and Eli Lilly are mentioned in the context of regional growth trends comparing Chinese and Western companies.
-
Michelle Xia Mentioned together
No evidence available to classify the relationship between Michelle Xia and Akeso.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
1 eventJune 2026
2 events- Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.
- A collection of industry news reported on June 6th, including Akeso's success reported by China Daily, the general trend of Chinese companies outpacing Western counterparts, and the ASCO meeting held in Chicago.